Novo Nordisk, Canada
Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country authorised to assist in chronic weight management and to reduce the risk of non-fatal myocardial infarction (MI) in adults with a body mass index (BMI) of 27 kg/m² or greater, who have established cardiovascular disease.
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
Wall Street Journal on MSN1d
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionThe Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
Novo Nordisk gained approval for Wegovy in China in June, and will initially target Chinese patients willing to pay ...
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback